Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Class of 2025
Hammarskjold High School
Superior Collegiate and Vocational Institute
Westgate Collegiate & Vocational Institute
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Personalis, Inc. - Common Stock
(NQ:
PSNL
)
6.370
-0.550 (-7.95%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 11, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Personalis, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Cramer Says Tesla Dominates While Ouster Is 'Too Speculative'
July 10, 2025
Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan American as a profitable alternative. Insmed is also considered speculative while the only viable option for...
Via
Benzinga
Topics
Artificial Intelligence
12 Health Care Stocks Moving In Wednesday's After-Market Session
July 09, 2025
Via
Benzinga
What's going on in today's after hours session
July 09, 2025
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
Via
Chartmill
Earnings Scheduled For May 6, 2025
May 06, 2025
Via
Benzinga
A Glimpse Into The Expert Outlook On Personalis Through 7 Analysts
February 28, 2025
Via
Benzinga
Earnings Scheduled For February 27, 2025
February 27, 2025
Via
Benzinga
Personalis Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
January 27, 2025
Via
Benzinga
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
July 09, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
June 03, 2025
From
Personalis, Inc.
Via
Business Wire
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
June 02, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
May 22, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference
May 14, 2025
From
Personalis, Inc.
Via
Business Wire
Analyst Expectations For Personalis's Future
May 07, 2025
Via
Benzinga
Personalis Reports First Quarter 2025 Financial Results
May 06, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis’ NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study
April 28, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis to Announce First Quarter 2025 Financial Results
April 22, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection
April 22, 2025
From
Personalis, Inc.
Via
Business Wire
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
April 17, 2025
A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.
Via
Investor's Business Daily
What 5 Analyst Ratings Have To Say About Personalis
April 10, 2025
Via
Benzinga
Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference
March 26, 2025
From
Personalis, Inc.
Via
Business Wire
This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
March 17, 2025
Via
Benzinga
Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip
March 08, 2025
Ark Invest made significant trades on Friday, selling shares of RBLX, ROKU, PATH and buying shares of IBTA, PSNL, ABSI, and RXRX.
Via
Benzinga
New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection
March 03, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis Reports Fourth Quarter and Full Year 2024 Financial Results
February 27, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference
February 18, 2025
From
Personalis, Inc.
Via
Business Wire
Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday
February 14, 2025
Via
Benzinga
Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results
February 13, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
January 28, 2025
From
Personalis, Inc.
Via
Business Wire
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer
January 13, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue
January 07, 2025
From
Personalis, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.